| UniProt ID | KCNJ8_HUMAN | |
|---|---|---|
| UniProt AC | Q15842 | |
| Protein Name | ATP-sensitive inward rectifier potassium channel 8 | |
| Gene Name | KCNJ8 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 424 | |
| Subcellular Localization |
Membrane Multi-pass membrane protein . |
|
| Protein Description | This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium (By similarity).. | |
| Protein Sequence | MLARKSIIPEEYVLARIAAENLRKPRIRDRLPKARFIAKSGACNLAHKNIREQGRFLQDIFTTLVDLKWRHTLVIFTMSFLCSWLLFAIMWWLVAFAHGDIYAYMEKSGMEKSGLESTVCVTNVRSFTSAFLFSIEVQVTIGFGGRMMTEECPLAITVLILQNIVGLIINAVMLGCIFMKTAQAHRRAETLIFSRHAVIAVRNGKLCFMFRVGDLRKSMIISASVRIQVVKKTTTPEGEVVPIHQLDIPVDNPIESNNIFLVAPLIICHVIDKRSPLYDISATDLANQDLEVIVILEGVVETTGITTQARTSYIAEEIQWGHRFVSIVTEEEGVYSVDYSKFGNTVKVAAPRCSARELDEKPSILIQTLQKSELSHQNSLRKRNSMRRNNSMRRNNSIRRNNSSLMVPKVQFMTPEGNQNTSES | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 6 | Phosphorylation | --MLARKSIIPEEYV --CCCCCCCCCHHHH | 28857561 | ||
| 62 | Phosphorylation | RFLQDIFTTLVDLKW HHHHHHHHHHHHHCH | 22817900 | ||
| 63 | Phosphorylation | FLQDIFTTLVDLKWR HHHHHHHHHHHHCHH | 22985185 | ||
| 194 | Phosphorylation | RAETLIFSRHAVIAV HHHHEEEECCEEEEE | - | ||
| 217 | Acetylation | FRVGDLRKSMIISAS EEECCCCHHHEEEEE | 7705923 | ||
| 275 | Phosphorylation | CHVIDKRSPLYDISA HHHHCCCCCCCCCCH | - | ||
| 278 | Phosphorylation | IDKRSPLYDISATDL HCCCCCCCCCCHHHH | - | ||
| 281 | Phosphorylation | RSPLYDISATDLANQ CCCCCCCCHHHHCCC | - | ||
| 283 | Phosphorylation | PLYDISATDLANQDL CCCCCCHHHHCCCCC | - | ||
| 329 | Phosphorylation | HRFVSIVTEEEGVYS CEEEEEEECCCCEEE | 26503514 | ||
| 335 | Phosphorylation | VTEEEGVYSVDYSKF EECCCCEEEEEHHHC | 26503514 | ||
| 336 | Phosphorylation | TEEEGVYSVDYSKFG ECCCCEEEEEHHHCC | 26503514 | ||
| 340 | Phosphorylation | GVYSVDYSKFGNTVK CEEEEEHHHCCCEEE | 26503514 | ||
| 372 | Phosphorylation | LIQTLQKSELSHQNS HHHHHCHHHHHHHHH | 26437602 | ||
| 375 | Phosphorylation | TLQKSELSHQNSLRK HHCHHHHHHHHHHHH | 28348404 | ||
| 379 | Phosphorylation | SELSHQNSLRKRNSM HHHHHHHHHHHHHHH | 28857561 | ||
| 397 | Phosphorylation | NSMRRNNSIRRNNSS HHHHHCCCCCCCCCC | 28674151 | ||
| 403 | Phosphorylation | NSIRRNNSSLMVPKV CCCCCCCCCCEEEEE | 27251275 | ||
| 404 | Phosphorylation | SIRRNNSSLMVPKVQ CCCCCCCCCEEEEEE | 24719451 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of KCNJ8_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of KCNJ8_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of KCNJ8_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
Oops, there are no PPI records of KCNJ8_HUMAN !! | ||||
| Kegg Disease | |
|---|---|
| There are no disease associations of PTM sites. | |
| OMIM Disease | |
| Note=Defects in KCNJ8 may be associated with susceptibility to J-wave syndromes, a group of heart disorders characterized by early repolarization events as indicated by abnormal J-wave manifestation on electrocardiogram (ECG). The J point denotes the junction of the QRS complex and the ST segment on the ECG, marking the end of depolarization and the beginning of repolarization. An abnormal J wave is a deflection with a dome or hump morphology immediately following the QRS complex of the surface ECG. Examples of J-wave disorders are arrhythmias associated with an early repolarization pattern in the inferior or mid to lateral precordial leads, Brugada syndrome, some cases of idiopathic ventricular fibrillation (VF) with an early repolarization pattern in the inferior, inferolateral or global leads, as well as arrhythmias associated with hypothermia. | |
| 272120 | |
| Kegg Drug | |
| D00631 | Bepridil hydrochloride hydrate (JAN); Bepridil hydrochloride (USAN); Vascor (TN) |
| D00636 | Amiodarone hydrochloride (JP16/USAN); Ancaron (TN); Cordarone (TN) |
| D02910 | Amiodarone (USAN/INN) |
| D06652 | Tedisamil (USAN) |
| D06653 | Tedisamil sesquifumarate (USAN) |
| D07520 | Bepridil (INN); Bepadin (TN) |
| DrugBank | |
| DB01251 | Gliquidone |
| DB01289 | Glisoxepide |
| DB01016 | Glyburide |
| DB00922 | Levosimendan |
| DB00914 | Phenformin |
| DB01154 | Thiamylal |
| DB01392 | Yohimbine |
loading...
